Skip to main content
. 2015 Aug 3;33(26):2841–2847. doi: 10.1200/JCO.2015.61.4776

Fig 1.

Fig 1.

Study cohort. IP/IV, intraperitoneal and intravenous; NCCN, National Comprehensive Cancer Network. (*) Propensity scores were overlapping (within 0.5%) for all but one patient who received IP/IV chemotherapy. For the rest of the patients who received IP/IV chemotherapy (n = 201), we obtained one matching patient who received IV chemotherapy using single nearest-neighbor without replacement.